Key Highlights

  • enGene (NASDAQ:ENGN) climbed 20.05% to USD 2.16 on November 12, 2026, as bladder cancer results put its complete response rate at 56% and a BLA submission on the calendar for year end.
  • Cumberland Pharmaceuticals (NASDAQ:CPIX) gained 17.32%, reaching USD 7.18, with cash of USD 80.6 million standing at roughly three quarters of its valuation.
  • Jin Medical International (NASDAQ:ZJYL) sank 36.35% without any news, while Estrella Immunopharma dropped 25.66% close to its Earnings timing.
  • NextPlat (NASDAQ:NXPL) lost 24%, ending at USD 6.30, even as its pharmacy operations expand; the float is roughly 1.5 million shares.

1. enGene (NASDAQ:ENGN)

enGene (NASDAQ:ENGN) has the strongest data underneath its move. The stock went from about USD 1.80 to USD 2.16, a 20.05% advance on 6.33 million shares, roughly 5.6 times normal activity. The trigger was a November 11 LEGEND study update in non-muscle invasive bladder cancer, and a brokerage lifted its rating to an overweight equivalent the next day. Across 120 evaluable patients, 56% reached complete response at some stage, versus 54% earlier, and 24% were in complete response at 12 months, against 13% previously. Among those who responded, 43% were still responding at 12 months (earlier 25%), median response duration rose to 10.1 months from 8.6, 97% stayed progression-free and 86% avoided cystectomy. Treatment-related adverse events affected 59% of patients, mainly Grade 1 to 2; Grade 3 events came to 4%, and there were no Grade 4 or 5 events. Management intends to start the BLA by the end of 2026, finish it in the first half of 2027, and anticipates possible approval in 2027. The risks include the modest Market Value of about USD 144.82 million, trailing losses of USD 2.08 per share, and the funding needed to reach approval, which could involve share sales. The next milestone is regulatory acceptance of the filing.

2. Cumberland Pharmaceuticals (NASDAQ:CPIX)

Cumberland Pharmaceuticals (NASDAQ:CPIX) rose 17.32% to USD 7.18 from about USD 6.12, with only 47,060 shares trading, roughly 0.19 times normal, following third-quarter results posted November 10 after the close. Net Income of USD 77.8 million came mainly from selling its commercial business, a deal finished July 1 for USD 100 million plus as much as USD 11 million more. Continuing Revenue was around USD 2.16 million, and the continuing loss shrank to about USD 1.12 million from USD 2.73 million. The USD 80.6 million of cash is roughly three quarters of the USD 107.58 million market value, an in-house calculation, after a USD 1.50 special payout on July 31 and an authorised buyback of up to 5 million shares. The pipeline is the unresolved part. Ifetroban for Duchenne cardiomyopathy has a new drug application under rolling review, and a Phase 2 trial produced a 5.4-point gain in left ventricular ejection fraction, though regulators suggested a Phase 3. A systemic sclerosis study failed on October 23 and the shares nearly halved. The cash provides a floor, and the remaining Business is a development story: second on data behind enGene, first on cash.

3. Jin Medical International (NASDAQ:ZJYL)

Jin Medical International (NASDAQ:ZJYL) slid 36.35% to USD 3.13 on about 85,680 shares, leaving a market value near USD 494.36 million, and no company statement turned up for November 10 to 12. This reverses an early November surge, including a 14.6% rise on November 9 that also lacked news, so the drop looks like a speculative unwinding, an interpretation. Fundamentals are soft. Revenue for the six months to March 31, 2026 declined 9.7% to USD 8.9 million, a net loss of USD 0.2 million was recorded, and full-year results to September 30 are still pending. Even post-drop, the stock trades near 20.86 times trailing diluted earnings of USD 0.15 per share, an elevated multiple for shrinking sales, while the screen shows earnings growth of minus 34.59%. A relative Volume of 0.19 means very little stock traded, so the headline fall reflects thin activity. A market value approaching half a billion USD against USD 8.9 million of half-year revenue has little support in disclosed figures. Updated results and evidence of capacity use would justify the valuation; until then the shares will probably follow flows in the market.

4. Estrella Immunopharma (NASDAQ:ESLA)

Estrella Immunopharma (NASDAQ:ESLA) dropped 25.66% to USD 0.5902 on about 638,360 shares, with a market value near USD 25.67 million, close to the expected date for quarterly results on November 11. No explanatory release was located, so the cause is unconfirmed. This clinical-stage company is evaluating its EB103 T-cell therapy in a Phase I/II trial for relapsed or refractory B-cell non-Hodgkin lymphoma, with five sites active, and brought in a new chief executive in late October. Trailing net losses come to roughly USD 10.01 million, or USD 0.25 per share, so a business with no revenue must raise money to complete the study. A share price under USD 1.00 heightens the chance of a Nasdaq bid price problem, and any raise at these levels would dilute heavily. The science remains early: a Phase I/II study in a crowded field of cell therapies can take years to Yield registrational data, and no efficacy findings were shared in the material reviewed. The new chief executive may reset strategy and financing, which adds uncertainty. Quarterly cash and the timing of interim trial data will reveal how long the runway is.

5. NextPlat (NASDAQ:NXPL)

NextPlat (NASDAQ:NXPL) dropped 24% to USD 6.30 on about 41,810 shares, roughly double its usual activity, giving a market value near USD 17.09 million, with no notice found for November 10 to 12 and a float of only about 1.5 million shares. The small float probably explains why light selling moved the price, an interpretation. The operating business is expanding. Second-quarter revenue grew about 21% on the first quarter to roughly USD 11.9 million, gross Margin hit a record near 40%, and the net loss narrowed to about USD 144,000, with cash near USD 11.9 million at June 30. In October it closed a pharmacy purchase in the Pensacola area, widening its pharmacy footprint and offering a route to inorganic growth. The comparison is sequential rather than year on year, and neither a consensus nor third-quarter figures were available. At roughly USD 6.30 with trailing losses of USD 3.70 per share on the screen, the shares stay small and thinly traded. Third-quarter numbers, not yet published, will show whether acquisitions and margin gains hold. NextPlat sits last because the move had no trigger and results are still outstanding.

Where Things Stand

enGene leads on evidence among the five healthcare names of November 12, given its 56% complete response rate and a BLA start targeted for year end 2026. Cumberland's cash approximates three quarters of its market value, Jin Medical trades at a lofty multiple on falling sales, Estrella is early-stage and NextPlat is expanding yet thinly traded. The coming checkpoints are enGene's BLA filing and NextPlat's third-quarter release.